

## Supplementary Table S4.

**Clinicopathological characteristics of patients of whom organoids were derived.** M: Male; F: Female; MSS: Microsatellite stable; PDX: Patient-Derived Xenograft; NA: Not Available; NM: Not Metastatic; met: metastasis. \*PR achieved when oxaliplatin was given both in first-line and in re-challenge setting (fifth line). PR: partial response; Beva: bevacizumab; Pani: panitumumab.

Patients										Organoids	
Patient ID	Age	Sex	Stage	Sideness	Molecular profile	First Site of metastases	Oxaliplatin-based Regimen (before tissue collection)	Line	Best Response	Type of Organoid	Tissue Collected
#1	76	F	IV	Right	MSS; BRAF V600E	Peritoneum	NO (FOLFIRI+Beva)	NA	NA	PDX-derived	Peritoneal met
#2	65	M	IV	Left	MSS; NRAS G12A	Liver	FOLFOX+Beva	1	PR	Patient-derived	Liver met
#3	76	F	IV	Rectum	MSS; HER2 ampl	Liver	FOLFOX+Beva	1	PR*	PDX-derived	Subcutaneous met
#4	56	M	IV	Left	MSS; RAS and BRAF WT	Liver	FOLFOX+Pani	1	PR	Patient-derived	Liver met
#5	74	F	I	Right	MSS; KRAS G12D	NM	-	-	-	Patient-derived	Primary tumor